New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

McDonald’s Corp. shares slipped on Tuesday after Redburn Atlantic gave the burger chain its sole sell rating, saying shifting ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

Appetite-suppressing GLP-1 drugs like Ozempic are reshaping consumer behaviour, posing a major challenge to fast-food chains ...

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

A recent study revealed that popular weight-loss drugs GLP-1 such as Ozempic, Wegovy and Zepbound produce lower weight loss ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.